ArticleHypertension research : official journal of the Japanese Society of Hypertension2026
Validity of risk stratification of JSH 2025 guideline based on hypertensive retinal changes.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We sought to assess the validity of risk stratification table of Japanese Society of Hypertension (JSH) 2025 guideline, based on Scheie hypertensive fundus changes. We analyzed the data of medical checkup of Saitama Red Cross Hospital from 2017 to 2024 who underwent fundus examination (N = 6953). Based on the risk stratification table of JSH 2025 guideline, age, sex, comorbidities, past history, and blood pressure (BP) at the health checkup examination were used to stratify the risk into 12 groups. As the original of this study, those with BP < 130/80 mmHg were further examined and a total of 15 groups were analyzed. Risk 1st category and BP < 130/80 mmHg were set as a control group. As the risk category and BP level each increased, the rate of Scheie hypertensive changes significantly increased. Samely, the rate of Scheie sclerotic changes also significantly increased. In the range of BP < 130/80 mmHg, the rate of fundus changes significantly increased as the risk category increased. In conclusion, the risk stratification table of JSH 2025 guideline was valid based on Scheie hypertensive changes in subjects with medical checkup. Furthermore, those with BP < 130/80 mmHg could be added in the risk stratification table.
Indexed as
Identifiers
41792247What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.